NR3C2 and hydrops fetalis: In large-scale clinical trials, RALES [16], EPHESUS [17], EMPHASIS-HF [18] and Aldo-DHF study [19], addition of an MR blocker to standard medical therapy including ACE-I or ARB had a beneficial effect on the prognosis of patients with HF or MI.